Abzena PLC (LON:ABZA)‘s stock had its “buy” rating reissued by equities researchers at FinnCap in a report released on Wednesday. They presently have a GBX 80 ($1.03) price objective on the stock. FinnCap’s price target suggests a potential upside of 79.78% from the company’s previous close.

Separately, Numis Securities Ltd reiterated a “buy” rating and issued a GBX 93 ($1.20) price objective on shares of Abzena PLC in a report on Friday, May 26th.

Abzena PLC (LON:ABZA) opened at 44.50 on Wednesday. The firm’s market cap is GBX 61.34 million. Abzena PLC has a 52 week low of GBX 31.00 and a 52 week high of GBX 66.00. The stock’s 50 day moving average is GBX 48.16 and its 200 day moving average is GBX 40.78.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/01/finncap-reiterates-buy-rating-for-abzena-plc-abza.html.

About Abzena PLC

Abzena plc is a life sciences company. The Company provides technologies and complementary services to enable the development and manufacture of biopharmaceutical products. It has a global customer base which includes approximately 20 biopharmaceutical companies, as well as large and small biotech companies and academic groups.

Receive News & Stock Ratings for Abzena PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abzena PLC and related stocks with our FREE daily email newsletter.